EKF diagnostic GmbH Launches ß-Hydroxybutyrate Strip Test at American Association for Clinical Chemistry 2013
7/24/2013 9:34:14 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Cardiff, UK – 24th July 2013 – EKF Diagnostics, the global in vitro diagnostics business, announces the worldwide launch of the new STAT-Site M ß-HB, following successful CE marking. The new quantitative strip-based test for ß-Hydroxybutyrate (ß-HB) provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds. STAT-Site M ß-HB will be premiered at Booth #3614 at the American Association for Clinical Chemistry’s Annual Meeting and Clinical Lab Expo (AACC 2013) in Houston, 30th July to 1st August.
The presence and degree of ketosis can be rapidly assessed at the point-of-care by accurately measuring blood levels of ß-HB, which accounts for 78% of the three ketone bodies, from just 10 µL of serum or plasma. This provides useful information to provide quality care when monitoring DKA in newly diagnosed patients, whilst also reducing time and costs in an intensive care unit setting .
Also at AACC, highlighting the clinical utility of ß-HB for the screening and diagnosis of ketosis, the AACC Industry Workshop ‘Metabolic Disturbances That Lead to ß-Hydroxybutyrate and Ketone Bodies’ will be hosted by EKF on Tuesday July 30, 7–8 am. This will be presented by point-of-care specialist Dr. James Nichols, Professor of Pathology, Microbiology & Immunology and Medical Director of Clinical Chemistry at Vanderbilt University School of Medicine. Attendees will learn about the critical inter-relationships of glucose, diabetes mellitus and conditions that lead to DKA. Early reservation via email@example.com is recommended as seating is limited.
Booth #3614 will play host to other very recently launched EKF products. These include another strip-based test for the rapid point-of-care analysis of hemoglobin for anemia determination, STAT-Site M Hgb. This hand-held analyzer combines low cost per test with portability and reliably delivers accurate hemoglobin results within 30 seconds from 15 µL of finger-prick whole blood.
AACC delegates will also have the opportunity to meet the new EKF Molecular Diagnostics’ team and view research use only products for cancer gene mutation enrichment and companion diagnostic applications. These include newly introduced PointMan™ DNA Enrichment kits which comprise three kits for enriching mutations in BRAF, KRAS and EGFR T790M genes associated with melanoma (skin cancer), colorectal and lung cancers. PointMan kits offer highly-specific and ultra-sensitive enrichment of mutant genes in a background of wild-type (normal) genes that is unmatched by existing technologies.
Julian Baines, Group CEO, commented, “This year’s AACC Clinical Lab Expo is the first time we have showcased our new EKF Molecular Diagnostics cancer gene detection technology portfolio alongside our clinical chemistry and near-patient testing products. Our experts will be on hand to discuss our ever broadening range of innovative and high-quality IVD diagnostics products. These are designed to rapidly and accurately detect and manage diabetes, anemia, lactate and kidney related diseases, as well as support better informed decisions on patient treatments through companion diagnostics.”
1) M. Vanelli, G. Chiari, C. Capuano, B. Iovane, A. Bernardini, T. Giacalone. PubMed - October 2003.
About EKF Diagnostics
EKF Diagnostics Holdings plc specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics.
Point-of-care diagnostics: EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to liquid reagent manufacture, design and building of world-class diagnostic devices, and distribution of rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Companion Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics - EKF Molecular Diagnostics develops technologies for cancer gene detection. Through its acquisition of UK-based 360 Genomics and by offering innovative products with the potential to change current DNA extraction and detection practices, EKF is addressing the fast growing companion diagnostics market.
EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
Help employers find you! Check out all the jobs and post your resume.